This antibody is specific against c-erbB-3 oncoprotein that is expressed in a variety of human normal, foetal and neoplastic epithelial tissues.
| Inventor | Institute |
|---|---|
| Bill Gullick | Imperial Cancer Research Fund |
| Cat. #: | 151157 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction |
| Application: | IHC ; IP ; WB |
| Target: | ErbB3 (Her3) |
| Reactivity: | Human |
| Clone: | RTJ1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody directed against ErbB3 kinase, widely prevalent in GI and breast tumours. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgM |
| Molecular weight: | 105 kDa |
| Immunogen: | Synthetic Peptide from C terminus of human c-erbB3 |
| Immunogen Uniprot ID: | P21860 |
| Myeloma used: | NS0 |
| Target background: | The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB3 is normally found in non-dividing differentiated epithelial cells, neurones and hepatocytes. ErbB3 was found to be kinase impaired, having only 1/1000 the autophosphorylation activity of EGFR and no ability to phosphorylate other proteins. Therefore, ErbB3 must act as an allosteric activator. The kinase-impaired ErbB3 is known to form active heterodimers with other members of the ErbB family, most notably the ligand binding-impaired ErbB2. It has approximately 80% prevalence in a wide variety of tumours of the gastro-intestinal tract, and approximately 20% prevalence in breast cancer. This antibody is specific against c-erbB-3 oncoprotein that is expressed in a variety of human normal, foetal and neoplastic epithelial tissues. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Li et al. 2017. Oncotarget. 8(40):67140-67151. PMID: 28978022. Lattanzio et al. 2016. Oncol Lett. 12(1):453-458. PMID: 27347164. Anagnostou et al. 2010. Cancer Epidemiol Biomarkers Prev. 19(4):982-91. PMID: 20332259. Analytic variability in immunohistochemistry biomarker studies. Kapitanovic et al. 2000. J Cancer Res Clin Oncol. 126(4):205-11. PMID: 10782893. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. Naidu et al. 1998. Br J Cancer. 78(10):1385-90. PMID: 9823984. Expression of c-erbB3 protein in primary breast carcinomas. Srinivasan et al. 1998. J Pathol. 185(3):236-45. PMID: 9771476. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. Rajkumar et al. 1996. Clin Mol Pathol. 49(4):M199-202. PMID: 16696074. c-erbB3 protein expression in ovarian cancer. Rajkumar et al. 1993. J Pathol. 170(3):271-8. PMID: 8133400. Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.